Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at other companies

Nuvation Bio logo
Nuvation BioNUVB
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's afs and trading securities - unrealized loss position (<12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's AFS and trading securities - unrealized loss position (<12 months) fair value?
Bicara Therapeutics (BCAX) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $156.24M in Q1 2026.